SUMMARY The Cambridge Low Contrast Gratings (CLCG) were used to assess contrast sensitivity (CS) in 39 patients with clinically definite multiple sclerosis and 60 control subjects. CS was determined in both horizontal and vertical orientations and compared with visual evoked responses (VERs) in the same populations. Only 33% ofpatients had abnormal CS whereas 82% had abnormal VERs. There was no correlation between the degree of abnormalities in CS and VERs. There was no significant difference between CS determined in the vertical and horizontal orientation; however, examination in the vertical orientation increased the number ofabnormalities detected by 2 (5%). We conclude that although CS, using the CLCG, is abnormal in a proportion of multiple sclerosis patients its detection is not clinically useful and is insensitive as a measure of subclinical optic neuropathy in multiple sclerosis. 
Discussion
In this study CS was impaired in only 33% of a population of clinically definite multiple sclerosis patients. Della Sala et al recently studied 48 multiple sclerosis patients using a similar test2 and found that 73% had abnormal CS. In both studies the incidence of VER abnormality was similar. The large discrepancy in CS abnormalities reported may be due to differences in examination methods and the groups studied. Our multiple sclerosis population consisted of clinically definite patients from a multiple sclerosis clinic, the only other criterion being normal visual acuity. The Italian study group had a high incidence of subjective ophthalmic complaints which may relate to the greater frequency of CS abnormalities found. The age structure in both studies was similar. In this study there was a 5% increase in abnormal CS scores by testing in two different orientations and previous reports of spatial orientation in VER testing have recorded a similar phenomenon.6 Thus CS is orientation sensitive and testing in different orientations can increase the sensitivity of the test.
The decline in CS with age in the control population and the approximation of means in the control and multiple sclerosis populations with increasing age renders CS testing over the age of 40 unproductive (only 13% ofour multiple sclerosis population over 40 years had abnormal CS).
The main object of this study was to determine whether CS testing using the CLCG was a useful clinical tool. The test is easy to perform, to interpret and examination in two orientations takes no longer than 10 minutes. The luminance requirements limit its use as a bedside or clinic test. We feel that the CLCG test of CS is unlikely to become a useful test of subclinical optic neuropathy in multiple sclerosis because of its low sensitivity, the requirement of normal visual acuity, age related decline in CS and the necessity to have a specially standardised area for its use.
